|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM150548257 |
| 003 |
DE-627 |
| 005 |
20250205203328.0 |
| 007 |
tu |
| 008 |
231223s2004 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed25n0502.xml
|
| 035 |
|
|
|a (DE-627)NLM150548257
|
| 035 |
|
|
|a (NLM)15380536
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Morita, Yasuyoshi
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system
|
| 264 |
|
1 |
|c 2004
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.10.2004
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Fractalkine (CX3CL1) and its receptor CX3CR1 play an important role in natural killer (NK) cell- and cytotoxic T cell-mediated endothelium damage. Here we describe the cytotoxicity of myelodysplastic syndrome (MDS)-derived T cell line, K2-MDS, through the fractalkine-CX3CR1 system. K2-MDS cells induced apoptosis against CD34(+) cells from normal bone marrow (BM) in a direct cell contact manner. K2-MDS cells expressed perforin and granzyme B, but they lacked Fas ligand expression. A specific inhibitor for perforin, concanamycin A, blocked K2-MDS-dependent cytotoxicity. Furthermore, a CX3C-chemokine, fractalkine, was expressed in CD34(+) cells, and its receptor, CX3CR1, was expressed on K2-MDS cells. The neutralizing monoclonal antibody (MoAb) for fractalkine and soluble fractalkine significantly inhibited K2-MDS-dependent cytotoxicity. K2-MDS cells also induced the cytotoxicity against human umbilical cord endothelial cells (HUVECs) expressing fractalkine. These data indicate that K2-MDS may be a perforin-granzyme-positive T cell line that exerts a cytotoxic effect on CD34(+) cells mediated through the fractalkine-CX3CR1 system
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antigens, CD34
|2 NLM
|
| 650 |
|
7 |
|a CX3C Chemokine Receptor 1
|2 NLM
|
| 650 |
|
7 |
|a CX3CL1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a CX3CR1 protein, human
|2 NLM
|
| 650 |
|
7 |
|a Chemokine CX3CL1
|2 NLM
|
| 650 |
|
7 |
|a Chemokines, CX3C
|2 NLM
|
| 650 |
|
7 |
|a Membrane Proteins
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Chemokine
|2 NLM
|
| 700 |
1 |
|
|a Matsuda, Mitsuhiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hanamoto, Hitoshi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shimada, Takahiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tatsumi, Yoichi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Maeda, Yasuhiro
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kanamaru, Akihisa
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 113(2004), 1 vom: 15. Okt., Seite 109-16
|w (DE-627)NLM098196855
|x 1521-6616
|7 nnns
|
| 773 |
1 |
8 |
|g volume:113
|g year:2004
|g number:1
|g day:15
|g month:10
|g pages:109-16
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 113
|j 2004
|e 1
|b 15
|c 10
|h 109-16
|